Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cell-based therapies for EBV-associated malignancies.

Graham S Taylor1

  • 1Cancer Research UK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK.

Expert Opinion on Biological Therapy
|December 19, 2003
PubMed
Summary

Epstein-Barr virus (EBV) specific T cell therapies show promise for treating EBV-associated malignancies like PTLD. Vaccine strategies are also being developed for widespread treatment and prevention of EBV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Beyond the Usual Suspects: Emerging Associations Between Epstein-Barr Virus Infection/Infectious Mononucleosis and Cancers.

Reviews in medical virology·2026
Same author

Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.

Infectious agents and cancer·2026
Same author

The T Cell Response to Epstein-Barr Virus.

Current topics in microbiology and immunology·2026
Same author

Multi-omic spatial profiling reveals the unique SARS-CoV-2 lung microenvironment and collagen VI as a predictive biomarker in severe COVID-19.

The European respiratory journal·2025
Same author

Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling.

iScience·2024

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Epstein-Barr virus (EBV) is linked to several human cancers.
  • EBV latent cycle genes in tumors offer targets for T cell immunotherapy.
  • Post-transplant lymphoproliferative disease (PTLD) is an EBV-associated malignancy.

Purpose of the Study:

  • To review the progress and challenges of T cell-based immunotherapies for EBV-associated malignancies.
  • To explore the potential of therapeutic and prophylactic vaccines against EBV.

Main Methods:

  • Review of clinical data and ongoing research in adoptive T cell transfer for EBV-associated diseases.
  • Discussion of vaccine development strategies for EBV.

Main Results:

Related Experiment Videos

  • Adoptive T cell transfer is effective for EBV-associated PTLD.
  • T cell therapies for other EBV malignancies are emerging but require significant lab support.
  • Vaccine strategies are under development for large-scale treatment and prevention.

Conclusions:

  • Adoptive T cell therapy is a viable treatment for EBV-associated PTLD.
  • Therapeutic vaccination may overcome limitations of T cell transfer for widespread EBV malignancy treatment.
  • Prophylactic vaccines could prevent primary EBV infection.